Publication number: 20240124451
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
Type:
Application
Filed:
September 21, 2023
Publication date:
April 18, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Donna A.A.W. Hayes, Prabha Karnachi, Madeleine Eileen Kieffer, Kyle S. McClymont, Rohan Rajiv Merchant, Essam Metwally, Anilkumar G. Nair, Ning Qi, Jillian Rose Sanzone, Nunzio Sciammetta, Emma H. Southgate, Zheng Tan, Brandon M. Taoka